Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 11/20 | 0.44 |
| ▸ | PDE6D | O43924 | 1/20 | 0.44 |
| ▸ | PDE6A | P16499 | 1/20 | 0.44 |
| ▸ | PDE6G | P18545 | 1/20 | 0.44 |
| ▸ | PDE6B | P35913 | 1/20 | 0.44 |
| ▸ | PDE6C | P51160 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359474 | 0.93 | SYK (0.46) | SYKCHEK1PDE2APDE6DPDE6A | |
| SCHEMBL5355066 | 0.83 | ADORA1 (0.48) | SYKCHEK1ADORA1 | |
| SCHEMBL5350666 | 0.83 | CHEK1 (0.43) | SYKCHEK1PDE2APDE10AADORA1 | |
| SCHEMBL5351538 | 0.76 | ADORA1 (0.44) | SYKPDE2AADORA1 | |
| SCHEMBL5354972 | 0.75 | ADORA1 (0.42) | CHEK1PDE2AADORA1 | |
| SCHEMBL5359370 | 0.72 | ACSS2 (0.45) | PDE2AADORA1 | |
| SCHEMBL5352149 | 0.72 | PDE2A (0.43) | SYKPDE2APDE6DPDE6APDE6G | |
| SCHEMBL5368068 | 0.71 | ADORA1 (0.40) | ADORA1 | |
| SCHEMBL545958 | 0.71 | PDE2A (0.43) | CHEK1PDE2APDE6DPDE6APDE6G | |
| SCHEMBL5355114 | 0.69 | ALDH1A1 (0.42) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | SYK 2389/4885CHEK1 1345/4885PDE2A 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.